Floatz logo

Kyv-101

Dermatomyositis

Kyverna TherapeuticsCell therapyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Dermatomyositis cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Northwestern University
Phase 2B
IMMUNOGLOBULIN G1, ANTI-(HUMAN LEUKOCYTE IG-LIKE RECEPTOR A4) (HUMAN MONOCLONAL VIB7734 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIB7734 .LAMBDA.-CHAIN, DIMER
Amgen
Phase 1CC
Nivolumab
National Cancer Institute (NCI)
Phase 1CC
Ipilimumab
National Cancer Institute (NCI)
Phase 1CC
Bms-907351
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Kyv-101 is also rated in:

primary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
secondary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
multiple sclerosisDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →